Human-in-the-loop AI needs a decision right, not an approval button

The signal: oversight belongs inside the workflow

The ISPE programme explicitly addresses human-in-the-loop governance for responsible AI. Our practical interpretation is that review needs to be designed before the workflow is automated. An approval button does not explain what the reviewer is checking, which evidence they can see or whether they can stop the proposed action. [1]

NIST's voluntary AI RMF Playbook provides a general reference for organizing AI risk work. Our proposal below is a domain-specific design exercise, not a claim that following it satisfies pharmaceutical requirements. The useful question is whether a scientist can recognize when the system's output should not be used. [2]

Human oversight needs competence, time and decision rights

Pharma 4.0 brings people and organizational design into the same scope as automation. An MSAT reviewer needs competence in the process, access to decisive records and enough protected time to challenge an AI-prepared packet. QA and manufacturing may hold different approval and action rights. Those responsibilities should be explicit before the interface offers an approval button. [4]

Train with a plausible wrong explanation, a missing method qualification and an unavailable calculation. Observe whether reviewers stop, ask for evidence and route the unresolved work. A culture that rewards only fast acceptance can defeat a technically careful review screen. Track correction effort and fallback alongside preparation speed.

Human oversight needs a competent reviewer with time, evidence and decision rights. An agent can coordinate scientific engines without inheriting authority over the operating decision.THE BIOMEDANA LENS

A hypothetical investigation assistant changes the review burden

Imagine an assistant preparing evidence for an unexpected impurity trend. It retrieves batch histories, finds analytical records and proposes three candidate explanations. The quality scientist receives a polished summary with a prominent recommendation. The underlying files are available, but reaching them requires several searches through another system.

The assistant has saved drafting time while potentially making challenge harder. A useful review view would put the decisive observations, contradictory evidence and missing records beside the proposed interpretation. The reviewer should be able to reject a hypothesis, request another analysis or hold the packet for clarification without losing the work already completed.

Give the reviewer a defined decision right

Write a short decision-right statement: the assistant may assemble and analyze authorized evidence for preparation; a named role decides whether the packet is suitable for the next investigation step. Define the action that remains outside the assistant's authority. Where a later process permits a controlled write, specify that permission separately from preparation and recommendation.

Distinguish scientific review, operational approval and record administration. The person checking an analytical comparison may not have authority to approve a manufacturing action. A generic approved state can conceal that difference. Retain who reviewed which proposition, the evidence version they reviewed and any conditions attached to the decision.

Design the agent boundary before the prompt

Our proposed agent contract describes allowed sources, allowed tools, input validation, execution limits, error handling and outputs. A tool that reads a batch history should not inherit permission to alter that history. Retrieved documents should remain evidence, not instructions that can grant the agent additional authority or redefine its task.

Test an untrusted source containing a command to disclose another study, a failed analytical service and a request that crosses a project boundary. The workflow should retain the reason for the failure and avoid filling the gap with a fluent answer. A safe fallback may be a partial packet with an explicit unresolved question for the reviewer.

Test the human-machine system, not only the answer

Prepare review exercises with a plausible but unsupported recommendation, a correct recommendation with poor evidence links and a contradictory record that arrives late. Ask reviewers to explain their decision and locate the supporting material. These exercises reveal whether the workflow makes challenge feasible under realistic time pressure.

Observe both overreliance and unnecessary rejection. A reviewer who rejects every machine output is not evidence that the tool is useful, while a reviewer who accepts every output may be missing meaningful exceptions. Record the circumstances that change decisions and use those observations to improve presentation, scope and training. Do not reduce oversight quality to an approval count.

Test a plausible answer with an unresolved conflict

Give the assistant an approved current method, an obsolete version and a later record whose authority is unresolved. Ask a question that depends on which instruction applies. A convincing answer with a real citation can still fail if it silently selects the wrong authority or omits a conflicting source.

The reviewer should be able to identify the conflict, inspect the source versions, withhold the unsupported conclusion and route the issue to the authorized owner. That is a stronger demonstration of oversight than approving a clean-looking draft. It tests the evidence path and the person's ability to challenge it.

Record the time needed for that review, material errors found or missed, corrections and escalation. Output accuracy and review effort are different measures. Even a mostly correct draft may require extensive checking when the reviewer cannot locate the remaining errors reliably.

Account for workload and escalation

Review obligations consume expert capacity. Decide what happens when the reviewer is unavailable, the queue grows or the evidence cannot be resolved within the expected time. An escalation path needs an owner and a usable record of what was attempted. Silence should not be interpreted as authorization to proceed.

We would measure review effort, unresolved exceptions, rework and time to a supported decision. If automation generates more candidate explanations than scientists can evaluate, constrain its output to the evidence and questions that matter for the next step. The purpose is to improve the decision, not maximize the volume of plausible analysis.

BioMedAna: agents coordinate science while reviewers retain the decision

BioMedAna’s AI layer is paired with scientific services rather than being the sole source of a numerical conclusion. An agent can assemble authorized evidence and invoke engineering calculations, chemistry models or a project-specific hybrid model. The resulting review should distinguish retrieved facts, computed quantities, model estimates and proposed interpretation.

That division makes oversight concrete. The scientist can inspect the calculation inputs and model scope, challenge the explanation and request another analysis. A physics or chemistry result does not grant the agent authority to approve a quality decision. The organization still needs trained reviewers, an agreed escalation path and a controlled record of what was accepted.

A review right and agent permission contract

An original BioMedAna working framework. Adapt the decisions and evidence to the actual process, people and intended use.

The questions behind the headline

Follow the evidence

1. ISPE 2026 Annual Meeting & Expo - live agenda, accessed 21 October 2026 ↗
2. NIST - AI RMF Playbook; voluntary guidance based on AI RMF 1.0 ↗
3. ICH Q10 - Pharmaceutical Quality System ↗
4. ISPE - Pharma 4.0 operating model: organizational, cultural, process and resource dimensions ↗

Original BioMedAna editorial analysis. The linked sources support the reported developments; examples, frameworks and product implications reflect our perspective.

Explore the underlying concepts

Explore the ISPE & Pharma 4.0 series ↗

• Agentic AI with deterministic GxP guardrails
• BioMedAna Assist & Agents
• API impurity investigation
• Evaluate a bioprocess AI platform